Kornimate/medical-research-clean huggingface dataset:
a mobile application for training of family caregivers caring for someone with dementia

Conditions: Dementia

Summary: background the mental, physical, and emotional health of caregivers is negatively affected by the burden of caring for of persons living with dementia. caregivers are usually reported as feeling frustrated, angry, exhausted, guilty, helpless and unable to bear the heavy burden of their caregiving responsibilities. in addition to depressive symptoms and other mental health problems among caregivers, the physical stress of caring for someone who is unable to perform daily activities such as bathing, grooming and other personal care, has been shown to be a serious threat to caregivers' physical health outcomes. evidence has shown that greater levels of stress, anxiety, depression, frustration, and lower subjective well-being and self-efficacy are exhibited in a greater amount among family and friends who care for persons living with dementia compared to those who do not have the burden of caring for a persons living with dementia. caregivers have been shown to use alcohol and other drugs at a higher rate than those who do not need to care for others as a reaction to this increased stress. studies has also shown that caregivers are more likely than non-caregivers to use opioid or psychotropic medications. one over five caregivers (22%) feel tired when they go to bed at night. objectives this study relies on a mobile application (caring4dementia) that provides people, caring for a person living with dementia, with a useful and intuitive training tool targeting communication skills. the aims of this study are to evaluate the feasibility and acceptability of using caring4dementia within a self-administered program and the preliminary efficacy of the caring4dementia intervention.


Eligibility criteria:
inclusion criteria: * informal caregiver of a person living with dementia for more than 6 months * able to read and understand english * able to use smartphones and tablets (apple or android) * have a smartphone or tablet (apple or android) with internet connection, involved in this study * 18 years or over * give written and oral informed consent exclusion criteria: * none

Keywords: dementia care-giving communication mobile application
study of verapamil in refractory epilepsy

Conditions: Epilepsy; Seizures

Summary: epilepsy is one of the most common chronic neurological diseases, affecting 300,000 canadians. one in 3 epilepsy patients have refractory seizures meaning that all antiseizure drugs fail to control their seizures. this drug resistance in epilepsy may be related to the over expression of multidrug resistance proteins (mdr). varapamil inhibits mdr. we propose to add verapamil/placebo to patients' anti epilepsy medication for 3 months. patients who receive placebo will have verapamil added for 3 months after the completion of the double-blind treatment period. seizure frequency/severity will be tracked. blood samples for dna will be collected. there will be 9 clinic visits over 32 weeks. ecg and echocardiogram will be done at baseline and repeated if necessary

this open label study will consist of three phases: baseline, double-blind treatment and open-label-treatment. there are 9 visits over 32 weeks. during the baseline period, the number of seizures will be recorded during 2 months while the patient is on a dose of antiseizure drug(s) that was previously established to provide better seizure control. blood work, including blood for dna baseline ecg and echocardiogram will be done and may be repeated if necessary. during the 3 months of double-blind treatment phase, verapamil/placebo will be added to the current medications. visits are every 4 weeks. vital signs, seizure counts and adverse events will be evaluated. all patients who received placebo will be offered 3 months of open-label treatment with verapamil.

Eligibility criteria:
inclusion criteria: * 1. patients in whom seizures are not controlled by their antiseizure medication; * 2. must have at least 2 seizures per month. exclusion criteria: * exclusion: patients with cardiovascular problems that could be adversely affected by verapamil

Keywords: refractory epilepsy- greater than 4 seizures in 2 month baseline period
institutional registry on outpatient and hospitalized covid-19 infected patients

Conditions: Covid19

Summary: creation of an institutional registry system for patients with confirmed covid-19 infection with the collection of epidemiological data, risk factors, diagnosis, prognoses, treatment, follow-up and survival.

ambispective observational cohort with administrative admission date corresponding to the day of positivity of the pcr test for covid-19, and discharge date of the cohort to the date corresponding to the epidemiological discharge, last contact with the health system and / or date of death. due to its institutional nature, the registry will collect data from the different patients who are assisted at different levels of the institution: emergency department, hospitalization in the general ward, critical areas, outpatient monitoring (including telemedicine) and home hospitalization.

Eligibility criteria:
inclusion criteria: * patient assisted by hiba adult services * patient diagnosed with covid-19
maximizing treatment outcome and examining sleep in post-traumatic stress disorder (ptsd)

Conditions: Post-Traumatic Stress Disorder

Summary: the purpose of this study is to examine the efficacy of exercise in comparison to wellness education to determine if they can improve the effects of prolonged exposure therapy (pe) in reducing symptoms of anxiety associated with post-traumatic stress disorder (ptsd). in addition, the two strategies (i.e., exercise and wellness education) will be compared in terms of improvements in sleep as well as levels of brain-derived neurotrophic factor (bdnf). bdnf is a protein that helps to support the survival of existing neurons and stimulate the growth new neurons and synapses. bdnf is important to learning and memory in general and therefore may be associated with the learning and memory as it relates to pe and corresponding symptom ptsd improvement.


Eligibility criteria:
inclusion criteria: * you have ptsd * you are between the age of 18 and 54 if female or between ages 18 and 44 if male. * you have written physician approval/medical clearance to participate in an exercise protocol. * are currently taking no psychotropic medications or are able and willing to discontinue these medications prior to the first pe session. exclusion criteria: * you are currently participating in a structured exercise program * you have severe depression * you have any history of bipolar disorder, psychotic disorder, or obsessive compulsive disorder; * you have a diagnosis of eating disorder, or substance abuse or dependence (excluding nicotine) within the past six months * you have any history of a suicide attempt, or are at significant risk of self-harm or harm to others * you have ever been diagnosed with organic brain syndrome, mental retardation, or other cognitive dysfunction

Keywords: ptsd anxiety behavior therapy prolonged exposure exercise wellness posttraumatic stress
palisade follow-on study (arc004)

Conditions: Peanut Allergy

Summary: the purpose of this study is to demonstrate the safety, tolerability, and efficacy of ar101 through oral immunotherapy (oit) in peanut-allergic children and adults who have completed the arc003 study.

this is an international, multicenter, open-label, 2-arm follow-on study of the safety, tolerability, and efficacy of ar101 in peanut-allergic individuals who have completed the arc003 study. this study will explore alternative dosing regimens during extended maintenance with ar101.

Eligibility criteria:
key inclusion criteria: * completion of the arc003 study * written informed consent and/or assent from subjects/guardians as appropriate * use of effective birth control by sexually active female subjects of child-bearing potential key exclusion criteria: * early discontinuation from the arc003 study * meets any longitudinally applicable arc003 study exclusion criteria * (group 2 only) failure to tolerate ≥ 443 mg cumulative of peanut protein with no or mild symptoms in the arc003 study exit dbpcfc * any other condition that, in the opinion of the investigator, precludes participation for reasons of safety

Keywords: ar101 characterized peanut allergen cpna (characterized peanut allergen) oit (oral immunotherapy) peanut allergy allergy peanut-allergic children peanut-allergic adults desensitization palisade
clinical pharmacology of platinum-based hyperthermic intraperitoneal chemotherapy

Conditions: Peritoneal Carcinomatosis

Summary: currently, there is a lack of knowledge on the effect of additional flushing after hipec on tumour platinum exposure, systemic platinum exposure and platinum concentration in drain exudate and thereby personal exposure. therefore the investigators want to perform a study to investigate the effect of flushing after hipec on tumour exposure, systemic exposure and on wound exudate concentration.

cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (hipec) is standard care in the treatment of patients with peritoneal carcinomatosis as a result of intra-abdominal cancers. in many (inter)national centres oxaliplatin is used for the primary hipec treatment. although the oxaliplatin dose of 460mg/m2 is widely accepted, the exact procedure of hipec differs between institutions and surgeons. due to a great variety in the volume of the abdominal cavity, platinum concentration in the perfusate might differ between patients. moreover, there is no consensus about the usefulness of flushing the hipec system with crystalloids at the end of oxaliplatin administration. flushing is predominantly performed with the idea to minimize both systemic exposure of ultrafilterable platinum and personnel exposure to platinum contaminated exudate. on the other hand, hipec without flushing might increase effectiveness because intraperitoneal tumour cells are exposed to high concentrations of oxaliplatin for a longer time period. the option of flushing is based on an individual preference of the surgeon. currently, there is a lack of knowledge on the effect of flushing on tumour platinum exposure, systemic platinum exposure and platinum concentration in drain exudate and thereby personal exposure. therefore the investigators want to perform a study to investigate the effect of flushing after hipec on tumour exposure, systemic exposure and on wound exudate concentration.

Eligibility criteria:
inclusion criteria: 1. subjects must provide written informed consent prior to performance of study-specific procedures or assessments and must be willing to comply with treatment and follow-up. note: informed consent may be obtained prior to start of the specified screening window. note: procedures conducted as part of the subject's routine clinical management (e.g., blood count, imaging study) and obtained prior to signing of informed consent may be utilized for screening or baseline purposes. 2. age ≥ 18 years 3. confirmed diagnosis of preoperatively identifi ed primary or recurrent peritoneal carcinomatosis (pc) of colorectal origin who are planned for hipec treatment with oxaliplatin according to routine clinical care exclusion criteria: 1) patients who do not achieve a cytoreduction score of cc-0 will be excluded from the study.

Keywords: hipec oxaliplatin flushing peritoneal carcinomatosis
non-pharmacological treatments for parasomnias

Conditions: NREM Parasomnia

Summary: the goal of this clinical trial is to compare the efficacy of non-pharmacological treatments (medical hypnosis and standard treatment) in patients with a non-rem parasomnia diagnosis. participants are randomly assigned to one of the two treatments. treatment consists of 3 sessions. participants receiving the standard treatment (i.e., sleep hygiene and episode risk reduction) may subsequently receive medical hypnosis. participation in the study involves 5 visits in total: 3 treatment visits and 2 study visits to the hospital (chuv). * an initial study visit to provide information and collect questionnaires prior to the start of treatment. an initial non-therapeutic hypnosis session will be carried out during electroencephalography. estimated duration: 2h. * a second study visit at the end of treatment, including questionnaires about your sleep and treatment. a shorter non-therapeutic hypnosis session and a second electroencephalography will be performed. estimated duration: 1h30. this visit may also be followed by an overnight polysomnography, according to patient's choice (if performed, estimated total duration 12 hrs). this study also involves monitoring patients' sleep for 10 nights before and after treatment: they will fill in a sleep diary and use an infrared camera.


Eligibility criteria:
inclusion criteria: * non-rem parasomnias diagnosis according to the international classification disease of sleep disorders * willling and able to give informed consent * reporting at least one parasomniac episode per month * reporting at least one parasomniac episode the month prior exclusion criteria: * refusal to use the home video recording device * current or planned intake (during the next 2 months) of medications/substances that may interfere with sleep architecture (e.g., hypnotics, neuroleptics, antidepressants, benzodiazepines) * a comorbid significant somatic disease altering the brain (e.g., cancer, epilepsy, multiple sclerosis, dementia) * a comorbid sleep disorder (e.g., apnea-hypopnea index (ahi) \>= 20/hour, rem sleep behaviour disorder, restless legs syndrome with symptoms more than 2 days/week) * a comorbid psychiatric disorder (e.g., severe depressive or anxiety disorder or psychotic disorder)

Keywords: medical hypnosis
dietary guide in active older adult men

Conditions: Men; Diet Modification; Obesity; Overweight; Life Style; Weight Loss

Summary: the present study aimed to determine the effects of negative-calorie diet supplemented with exercise, on weight loss and lipid profile, and to compare its efficiency with low-calorie diet with exercise among elderly adult men with abnormal weight gain.

background and aim: negative-calorie diet is among the popular dieting guides for weight loss; however, there is still little knowledge about this method. the present study aimed to determine the effects of negative-calorie diet supplemented with exercise, on weight loss and lipid profile, and to compare its efficiency with low-calorie diet with exercise among elderly adult men with abnormal weight gain. materials and methods: participants included sedentary men (age 45-75 years) with overweight or obesity (n=37). they were randomly divided into 2 groups including negative calorie diet with exercise, and low-calorie diet with exercise. of all 37 participants, 30 persons completed the treatment. the weight assessment parameters including change in weight and body composition, blood sample tests were performed pre- and three month post-intervention.

Eligibility criteria:
inclusion criteria: non-smokers and weight-stable (± 2 kg, for more than one year) with no history of regular exercise in at least three months before the study. exclusion criteria: history of cvd and other disorders such as diabetes, depression, eating disorders, chronic medications, kidney disease, cancer, food allergies or intolerances to items used in meals. subjects with abnormality in thyroid or electrocardiograph, any history of anti-obesity medication or weight loss drugs or dietary supplementations for weight control.

Keywords: caloric restriction diet exercise obesity overweight sedentary lifestyle weight loss men
aripiprazole for neuroleptic-induced tardive dyskinesia

Conditions: Dyskinesia, Drug-Induced

Summary: the aim of the present study was to investigate the efficacy of aripiprazole in management of pre-existing neuroleptic-induced tardive dyskinesia

objective:a few case reports on the use of aripiprazole in neuroleptic-induced tardive dyskinesia have demonstrated positive effects. however its effectiveness in treatment of td was still inconclusive. the aim of the present study was to investigate the efficacy of aripiprazole in management of pre-existing neuroleptic-induced tardive dyskinesia. method: subjects with pre-existing neuroleptic-induced tardive dyskinesia were chosen from taoyuan psychiatric center. patients recruited would be treated with aripiprazole for cross-titration with previous antipsychotics in 8 weeks. we use aims, sas, \& bas to assess the severity of tf and eps. we record subjects' age, sex, and other factors which have influence at the treatment response. subjects are assessed every two weeks in the first month and then monthly until six months.

Eligibility criteria:
inclusion criteria: * female patients must agree to prevent from being pregnant during trial periods * meet psychotic disorder or mood disorder criteria of dsm-iv * patients must have psychiatric diseases that need to use antipsychotics for a long time * they must meet dsm-iv research criteria for neuroleptics induce tardive dyskinesia * no clinical significant major systemic diseases * no special neurological diseases which would influence the assessment for eps or td * mentality is better than mild mental retardation * patients or .legal representatives agree to join in the research and sign informed consent. exclusion criteria: * unstable major systemic diseases * had neurological disorder influenced to eps assessment * substance abuse or dependence other then coffee or tobacco within 6 months before study

Keywords: aripiprazole tardive dyskinesia
cellulitis optimal antibiotic treatment

Conditions: Cellulitis of Leg

Summary: to determine whether a short course of oral flucloxacillin (5 days) is non-inferior to a standard course (7 days) in terms of pain over days 6-14 (indicative of persistence or recurrence associated with the symptoms of most importance to patients) in adults with cellulitis of the leg presenting in primary care.

cellulitis is a deep infection of the skin and subcutaneous tissues and most often occurs in the legs. it is a painful condition that is associated with inflammation and swelling of the site, and often systemic symptoms such as fever, headache, muscle aches, malaise, and fatigue. patients report feeling unwell and that it has a significant impact on their mobility and ability to carry out their usual activities. nice guidelines recommend oral flucloxacillin 500-1000 mg four times daily for 5-7 days as first-line treatment for most patients with cellulitis in the community, but most prescriptions are dispensed for a 7-day course. we will be assessing the effectiveness and safety of a 5-day treatment vs. the standard 7-day treatment. we also aim to evaluate the cost-consequences of a shorter course from an nhs and personal perspective. participants will be randomly allocated to one of two groups. in addition to usual care, participants will either be assigned to a 5-day oral flucloxacillin course or a standard 7-day flucloxacillin course. participants will be prescribed a 5-day course of oral flucloxacillin, and two additional tablets will be posted to the participants which will either be the antibiotic or a placebo tablet. participants will be asked to fill out daily questionnaires and express their experiences with the shortened course and taking part in the trial.

Eligibility criteria:
inclusion criteria: * must be aged 18 years or older * currently showing symptoms of cellulitis (such as pain, tenderness, redness, other change in skin color, warmth to touch) in one leg for 10 days or less * pain rated as 3/10 or higher on a numerical rating scale (0-10) at baseline assessment * be willing to be randomized to either trial arm (5-day or 7-day treatment) * able to complete trial procedures in the english language. exclusion criteria: * have penicillin allergy * have bilateral cellulitis * have had antibiotics for cellulitis within the past month * have post-operative cellulitis (within 30 days of operative procedures on the same leg) * have cellulitis resulting from human/animal bite injury * have cellulitis associated with chronic (\>6 weeks) leg ulceration * require immediate hospital admission or out-patient intravenous antibiotic therapy

Keywords: primary care antibiotic treatment antibiotic resistance pain cost consequences
patient participation in prevention of loss of functions

Conditions: Dementia; Malnutrition; Depression; Pain; Quality of Life

Summary: randomized clinical trial (rct) to investigate and compare the effect of two preventive interventions on readmission rates, loss of functions, quality of life and cost-benefit.

at baseline: nutritional status, bmi and weight, depression (gds5), dementia (mmse), pain (verbal ranking scale), muscle strength (hand-grip strength, chair-to-stand-test), quality of life (eq5d), coping (sense of coherence 13 item scale), patient experience (norpeq), medication management (medmaide). at follow-up three months after discharge: bmi and weight, depression (gds5), dementia (mmse), pain (verbal ranking scale), muscle strength (hand-grip strength, chair-to-stand-test) and eq5d. in addition, need for initiated municipal assistance after discharge. project employee who performs data collection is blinded to the group to which the patient is randomized. the control group patients in the control group undergo the same measurements and registrations at discharge and 3 - month follow-up, as the intervention groups, but receive otherwise usual treatment and care, and are discharged without further intervention. after six months control patients receive a report comprising the screening results, relevant information material and a cover letter. patients' gp and municipality care section receive a summary of outcomes, as well as a cover letter. register data information on mortality, readmissions and services in primary health care are obtained after 6 months from the national patient register, population register and municipalities.

Eligibility criteria:
inclusion criteria: * 65 years or older * living in their own home with no contact to the municipality, both before and after admission * discharged from department o105 or the acute receiving unit \<48 hours from admission. exclusion criteria: * patients with life-threatening disease in the terminal stage * patients who does not speak and understand danish * patients who are not able to communicate and collaborate, with regards to the measurements
correlative study on incidence and risk factors of glaucoma-related adverse event at various durations after congenital cataract surgery

Conditions: The Incidence and Risk Factors of Glaucoma After Congenital Cataract Surgery

Summary: a retrospective chart review of 264 eyes from 177 patients was performed who underwent congenital cataract surgery before the age of 14 years. all patients' surgery was performed by the same experienced surgeon at the eye hospital of wenzhou medical university from may 2011 to march 2019. we recorded patient demographics and incidence and risk factors for glaucoma-related adverse event. this study to identify the incidence of and risk factors associated with postoperative glaucoma at various durations after congenital cataract surgery.


Eligibility criteria:
inclusion criteria: * patients who underwent lensectomy combined with limited anterior vitrectomy, with or without iol implantation for congenital cataract, all by one surgeon exclusion criteria: * patient had a preoperative iop above 21mmhg, glaucoma, coexistent uveitis, metabolic syndromes/diseases or exposure to radiation.

Keywords: glaucoma incidence congenital cataract surgery